Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : FDA Grants Priority Review to J&J's Bedaquiline Tuberculosis Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 04:02pm CEST
   By Nathalie Tadena 
 

The Food and Drug Administration has granted accelerated approval for Johnson & Johnson's (JNJ) drug to treat a drug-resistant form of tuberculosis.

The drug, bedaquiline, has faced concerns about an imbalance of deaths seen in clinical studies. J&J's Janssen Research & Development had asked the FDA for accelerated approval of bedaquiline, which is a type of temporary approval based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group--but the prescribing information for the treatment will include boxed warnings regarding increased risk of death.

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether bedaquiline played a role in deaths seen in clinical studies. While the FDA has said the safety data currently available for bedaquiline suggest the product appears safe, there is a potential for the highest dose of the product to cause a small change in the heart's rhythm. The FDA had said there wasn't enough data to rule out potential drug side effects on the liver and the heart. There were more deaths seen among patients being treated with bedaquiline although most of the deaths were attributed to the underlying disease.

The consumer group Public Citizen has strongly opposed the accelerated approval of bedaquiline because clinical trials showed the drug could be highly dangerous.

Only about 100 cases of drug-resistant TB are seen each year in the U.S. but the problem is more severe in typically poor countries outside the U.S.

Tuberculosis is a bacterial infection that mostly involves the lungs. It is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Bedaquiline is designed to work in a new way to treat TB and would be used with other drugs.

However, there is evidence that some forms of TB can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the worldwide control of tuberculosis."

Tuberculosis can be fatal if it's not properly treated.

Write to Nathalie Tadena at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:39a JOHNSON & JOHNSON : scores $260M+ DOD orthopedics contract
04/28 JOHNSON & JOHNSON : Janssen Research & Development Submits Supplemental New Drug..
04/28 JOHNSON & JOHNSON : How Johnson & Johnson Is Leading When It Comes to Military L..
04/28 ACTELION : Publication of the definitive notice of the end result of Actelion te..
04/28 JOHNSON & JOHNSON : European Commission Extends Approval for Janssen’s DAR..
04/28 JOHNSON & JOHNSON : Sharon Kleyne & Neville L. Johnson Explore Privacy & Bullies..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 DAILY DIVIDEND REPORT : Xom, jnj, su, xlnx, pfe, cvx, ko
04/27 JOHNSON & JOHNSON : Dr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance..
04/27 JOHNSON & JOHNSON : Announces Dividend Increase of 5.0%
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 JOHNSON & JOHNSON : 55 Years Of Increasing Dividends, A Company For All Seasons
04/28 HOW TO POSITION YOUR PORTFOLIO FOR T : 3 Actionable Steps
04/28 How Low Can You Go? U.S. Pharma Already Shoulders Light Tax Burden
04/28 Calling All Heart Docs - Your Diabetes Drugs Need You
04/28 Johnson & Johnson (JNJ) Investor Presentation - Slideshow
Advertisement
Financials ($)
Sales 2017 75 666 M
EBIT 2017 23 472 M
Net income 2017 17 913 M
Debt 2017 8 242 M
Yield 2017 2,73%
P/E ratio 2017 18,82
P/E ratio 2018 16,91
EV / Sales 2017 4,53x
EV / Sales 2018 4,33x
Capitalization 334 714 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
SANOFI11.79%121 897
More Results